Abstract
Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1.4 million patients diagnosed with cancer each year in the USA. This condition is characterized by progressive deterioration of a patient's nutritional status, weight loss, anorexia, diminished quality of life and increased mortality and morbidity. Current therapy with progestational, anti-inflammatory and anabolic agents is often ineffective and has a large number of undesirable effects. The newly developed nonsteroidal selective androgen receptor modulator Ostarine™ has demonstrated promising results in Phase I and II clinical trials, increasing total lean body mass, enhancing functional performance and decreasing total tissue percent fat. This selective androgen receptor modulator may have the ability to perform as a potent anabolic agent with minimal side effects on other organs (prostate and hair follicles), thus presenting a new strategy in managing cancer cachexia. However, more extensive data is required before its efficacy is confirmed.
Original language | English (US) |
---|---|
Pages (from-to) | 1211-1220 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 5 |
Issue number | 8 |
DOIs | |
State | Published - Dec 1 2009 |
Keywords
- Androgen receptor
- Aryl propionamide
- Cancer cachexia
- GTx-024
- MK-2866
- Muscle wasting
- Nonsteroidal androgen
- Ostarine™
- Selective androgen receptor modulator
- Testosterone
ASJC Scopus subject areas
- Oncology
- Cancer Research